DE2002816A1 - Heilmittel - Google Patents
HeilmittelInfo
- Publication number
- DE2002816A1 DE2002816A1 DE19702002816 DE2002816A DE2002816A1 DE 2002816 A1 DE2002816 A1 DE 2002816A1 DE 19702002816 DE19702002816 DE 19702002816 DE 2002816 A DE2002816 A DE 2002816A DE 2002816 A1 DE2002816 A1 DE 2002816A1
- Authority
- DE
- Germany
- Prior art keywords
- diazepam
- propantheline
- halide
- bromide
- acid addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 23
- 229960003529 diazepam Drugs 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 18
- -1 propantheline halide Chemical class 0.000 claims description 18
- 229960000697 propantheline Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 11
- 229960005439 propantheline bromide Drugs 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- BPYZIOINRAWEQL-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2-one;hydrochloride Chemical compound Cl.N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 BPYZIOINRAWEQL-UHFFFAOYSA-N 0.000 claims description 3
- 239000012876 carrier material Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000463 material Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 206010007645 Cardiospasm Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- LGRQVEDRZGRZRJ-UHFFFAOYSA-K aluminum;calcium;carbonate;hydroxide Chemical compound [OH-].[Al+3].[Ca+2].[O-]C([O-])=O LGRQVEDRZGRZRJ-UHFFFAOYSA-K 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940097896 diazepam 5 mg Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013864 duodenitis Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- QXUAFCKBYYPTPQ-ZWKAXHIPSA-L magnesium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol octadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QXUAFCKBYYPTPQ-ZWKAXHIPSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 206010037628 pylorospasm Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79354669A | 1969-01-23 | 1969-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2002816A1 true DE2002816A1 (de) | 1970-07-30 |
Family
ID=25160159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19702002816 Pending DE2002816A1 (de) | 1969-01-23 | 1970-01-22 | Heilmittel |
Country Status (10)
| Country | Link |
|---|---|
| AT (1) | AT297216B (enExample) |
| BE (1) | BE744704A (enExample) |
| DE (1) | DE2002816A1 (enExample) |
| ES (1) | ES375750A1 (enExample) |
| FR (1) | FR2034484B1 (enExample) |
| GB (1) | GB1263235A (enExample) |
| IE (1) | IE33949B1 (enExample) |
| MY (1) | MY7300041A (enExample) |
| NL (1) | NL157802B (enExample) |
| SE (1) | SE366917B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4126672A (en) | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US7371831B2 (en) | 2001-02-09 | 2008-05-13 | Clariant Finance (Bvi) Limited | Azo dyestuffs |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3714355A (en) * | 1971-05-06 | 1973-01-30 | Hoffmann La Roche | Medazepam and propantheline composition |
-
1970
- 1970-01-12 NL NL7000354A patent/NL157802B/xx unknown
- 1970-01-14 GB GB175470A patent/GB1263235A/en not_active Expired
- 1970-01-20 IE IE6770A patent/IE33949B1/xx unknown
- 1970-01-21 BE BE744704D patent/BE744704A/xx unknown
- 1970-01-22 FR FR7002291A patent/FR2034484B1/fr not_active Expired
- 1970-01-22 AT AT59570A patent/AT297216B/de not_active IP Right Cessation
- 1970-01-22 DE DE19702002816 patent/DE2002816A1/de active Pending
- 1970-01-22 ES ES375750A patent/ES375750A1/es not_active Expired
- 1970-01-23 SE SE87870A patent/SE366917B/xx unknown
-
1973
- 1973-12-30 MY MY7300041A patent/MY7300041A/xx unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4126672A (en) | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US7371831B2 (en) | 2001-02-09 | 2008-05-13 | Clariant Finance (Bvi) Limited | Azo dyestuffs |
Also Published As
| Publication number | Publication date |
|---|---|
| AT297216B (de) | 1972-03-10 |
| FR2034484A1 (enExample) | 1970-12-11 |
| GB1263235A (en) | 1972-02-09 |
| SE366917B (enExample) | 1974-05-13 |
| MY7300041A (en) | 1973-12-31 |
| IE33949L (en) | 1970-07-23 |
| BE744704A (fr) | 1970-07-22 |
| IE33949B1 (en) | 1974-12-30 |
| ES375750A1 (es) | 1972-05-16 |
| NL7000354A (enExample) | 1970-07-27 |
| NL157802B (nl) | 1978-09-15 |
| FR2034484B1 (enExample) | 1973-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60207383T2 (de) | Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen | |
| DE3688296T2 (de) | Arzneimittel zur behandlung von erbrechen. | |
| DE69435095T2 (de) | Neue Behandlungsmethoden durch Verwendung von Phenethylaminderivaten | |
| DE69732113T2 (de) | Schnelllösliche tablette enthaltend galanthaminhydrobromid | |
| AT401468B (de) | Pharmazeutische zusammensetzungen mit einem gehalt an ranitidinwismutcitrat | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE3101644A1 (de) | Arzneimittelpraeparate und verfahren zu ihrer herstellung | |
| EP0675717A1 (de) | Verwendung von 2-amino-6-a-propyl-amino-4,5,6,7-tetrahydrobenzothiazol (pramipexol) als arzneimittel mit antidepressiver wirkung | |
| DE19906310A1 (de) | Arzneimittel zur Behandlung von Bluthochdruck | |
| DE69420776T2 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| DE2513940A1 (de) | Pharmazeutische zubereitung | |
| EP0689837A2 (de) | Antihyperglykämisch wirksame Arzneimittel | |
| DE69131398T2 (de) | Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall | |
| DE60204694T2 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
| DE2002816A1 (de) | Heilmittel | |
| DE69903716T2 (de) | Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten | |
| DE3301328A1 (de) | Arzneimittel zur einleitenden bekaempfung von akuter oder chronischer, myelogener leukaemie | |
| WO1983001570A1 (fr) | Produit pharmaceutique et son procede de preparation | |
| DE69004529T2 (de) | Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen. | |
| EP0000015B1 (de) | Arzneimittel zur Behandlung von Depressionen | |
| DE2219989A1 (de) | Heilmittel | |
| DE2636328A1 (de) | Arzneimittel | |
| DE3933738A1 (de) | Neue verwendung von 2-aminothiazol-derivaten (tsh) | |
| EP0219728A1 (de) | Kombinationspräparat | |
| DE2500656C2 (enExample) |